China’s war on corruption is overdue. Its allegations of bribery against GlaxoSmithKline are evidence that it is serious – and on Monday, the company acknowledged that some local executives appeared to have violated Chinese laws. But the anti-corruption battle is just one aspect of China’s drug market that foreign companies need to factor in. Healthcare reform and a push to build a strong local pharma industry are bigger long-term challenges.
中國早就該對腐敗開戰了。對葛蘭素史克(GSK)的腐敗指控表明，中國的態度是認真的。周一，該公司承認，一些中國本土高管違反了中國法律。但反腐斗爭只是在中國藥品市場中的外資醫藥企業需要考慮的一個因素。中國醫療改革和推動建立一個更強大的本土醫藥行業的努力，是外資藥企面臨的更大的長期挑戰。
您已閱讀23%（587字），剩余77%（1980字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。